Nureca
- P/E
- 70.21
Key Fundamentals
MicrocapHealthcare Equipment & SuppliesHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 3.30%
- Debt to Equity
- 0.01
- EPS (TTM)
- ₹4.38
- Book Value
- ₹196.90
- Market Cap
- —
- P/E (TTM)
- 70.21
- P/B
- 1.56
- ROE
- 1.12%
- Dividend Yield
- 0.98%
- EBITDA
- ₹8.30 Cr
- 52W High
- ₹376.00
- 52W Low
- ₹204.00
- Day Range
- ₹295.30 – ₹313.20
- Volume
- 2,920
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 66
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 38
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 71
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 85
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 67
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 64
- Good
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Promoter holding has increased by 2.59% over last quarter.
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -7.19% over past five years.
- Company has a low return on equity of -0.56% over last 3 years.
- Earnings include an other income of Rs.7.35 Cr.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 7 | 7 | 5 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Neutral | 5 | 0 | 5 |
Oscillators
Bearish
Overall
Bearish
Moving Averages
Neutral
Key readings
- RSI (14)
- 43.77
- Neutral
- MACD (12,26,9)
- −8.59
- Bearish
- SMA (50)
- 326.97
- Bearish
- SMA (200)
- 286.24
- Bullish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 5Y | −7.15% |
|---|---|
| 3Y | +9.82% |
| 1Y | +33.64% |
| TTM | +23.92% |
Net profit
| 5Y | −46.59% |
|---|---|
| 3Y | Turned to profit |
| 1Y | +100.00% |
| TTM | Tiny base |
Operating cash flow
| 5Y | −38.82% |
|---|---|
| 3Y | −33.06% |
| 1Y | Turned positive |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | −29.11 pp |
|---|---|
| 3Y | +13.51 pp |
| 1Y | +7.27 pp |
| TTM | +7.35 pp |
Revenue by year
| Mar 2019 | ₹62.00 Cr |
|---|---|
| Mar 2020 | ₹99.00 Cr |
| Mar 2021 | ₹213 Cr |
| Mar 2022 | ₹256 Cr |
| Mar 2023 | ₹111 Cr |
| Mar 2024 | ₹92.00 Cr |
| Mar 2025 | ₹110 Cr |
| Mar 2026 | ₹147 Cr |
Net profit by year
| Mar 2019 | ₹6.00 Cr |
|---|---|
| Mar 2020 | ₹6.00 Cr |
| Mar 2021 | ₹46.00 Cr |
| Mar 2022 | ₹45.00 Cr |
| Mar 2023 | −₹8.00 Cr |
| Mar 2024 | −₹2.00 Cr |
| Mar 2025 | ₹1.00 Cr |
| Mar 2026 | ₹2.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.23 | 31.35 | 22.37 | 16.97 | 20.27 | 31.19 | 26.46 | 31.74 | 34.18 | 37.74 | 39.64 | 35.41 | 40.34 | 58.53 |
| Expenses | 24.13 | 29.97 | 26.62 | 21.4 | 22.63 | 33.54 | 30.47 | 30.54 | 34.74 | 34.47 | 36.39 | 41.19 | 36.92 | 53.3 |
| Operating Profit | −2.9 | 1.38 | −4.25 | −4.43 | −2.36 | −2.35 | −4.01 | 1.2 | −0.56 | 3.27 | 3.25 | −5.78 | 3.42 | 5.23 |
| OPM % | −13.66% | 4.4% | −19% | −26.1% | −11.64% | −7.53% | −15.15% | 3.78% | −1.64% | 8.66% | 8.2% | −16.32% | 8.48% | 8.94% |
| Other Income | 2.67 | 3.2 | 5.9 | −1.26 | 5.79 | 3.17 | 1.48 | 1.99 | 2.57 | 2.32 | 2.19 | 1.02 | 1.82 | 1.35 |
| Interest | 0.12 | 0.08 | 0.11 | 0.18 | 0.15 | 0.27 | 0.18 | 0.62 | 0.25 | 0.46 | 0.28 | 0.3 | 0.2 | 0.26 |
| Depreciation | 0.58 | 0.59 | 0.59 | 0.6 | 0.66 | 0.62 | 0.54 | 0.52 | 0.53 | 0.54 | 0.5 | 0.45 | 0.61 | 0.81 |
| PBT | −0.93 | 3.91 | 0.95 | −6.47 | 2.62 | −0.07 | −3.25 | 2.05 | 1.23 | 4.6 | 4.66 | −5.51 | 4.43 | 5.52 |
| Tax % | −23.66% | 25.83% | 82.11% | −35.86% | 36.64% | 585.71% | −13.85% | −20% | 34.15% | 21.13% | 19.96% | 10.71% | 30.93% | 26.63% |
| Net Profit | −0.71 | 2.89 | 0.17 | −4.15 | 1.66 | −0.48 | −2.8 | 2.47 | 0.81 | 3.63 | 3.73 | −6.09 | 3.07 | 4.05 |
| EPS (₹) | −0.71 | 2.89 | 0.17 | −4.15 | 1.66 | −0.48 | −2.8 | 2.47 | 0.81 | 3.63 | 3.91 | −6.38 | 3.22 | — |
Sep 2026: from the results filed on 21 Oct 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 62 | 99 | 213 | 256 | 111 | 92 | 110 | 147 | 153 |
| Expenses | 53 | 90 | 152 | 200 | 126 | 102 | 117 | 147 | 149 |
| Operating Profit | 9 | 10 | 62 | 56 | −15 | −10 | −8 | 0 | 4 |
| OPM % | 15% | 10% | 29% | 22% | −13% | −11% | −7% | 0.1% | 2.7% |
| Other Income | 0 | 0 | 3 | 8 | 7 | 11 | 12 | 8 | 7 |
| Interest | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 |
| PBT | 9 | 9 | 62 | 61 | −11 | −3 | 1 | 5 | 8 |
| Tax % | 30% | 26% | 26% | 26% | −23% | −30% | 37% | 58% | — |
| Net Profit | 6 | 6 | 46 | 45 | −8 | −2 | 1 | 2 | 4 |
| EPS (₹) | Not comparable with later periods: it is stated on a share count about a hundred times or more different, so it is left blank. | Not comparable with later periods: it is stated on a share count about a hundred times or more different, so it is left blank. | 46.37 | 44.96 | −8.25 | −1.79 | 0.85 | 2.18 | 4.38 |
| Div. Payout % | 0% | 0% | 4% | 7% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 8 | 15 | 153 | 193 | 185 | 183 | 184 | 171 |
| Borrowings | 0 | 10 | 4 | 4 | 3 | 3 | 5 | 2 |
| Other Liabilities | 15 | 9 | 19 | 12 | 8 | 10 | 11 | 13 |
| Total Liabilities | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 196 |
| Fixed Assets | 1 | 1 | 4 | 10 | 9 | 7 | 9 | 14 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 33 | 59 | 94 | 1 | 1 |
| Other Assets | 23 | 33 | 182 | 175 | 139 | 104 | 200 | 182 |
| Total Assets | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 196 |
Cash Flow
₹ Cr| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | 0 | −8 | 35 | 1 | 10 | −3 | −19 | 3 |
| Investing | 0 | 0 | −110 | −3 | −16 | 18 | 8 | 14 |
| Financing | 0 | 8 | 92 | −7 | −2 | −1 | 0 | −20 |
| Net Cash Flow | 0 | 0 | 17 | −9 | −8 | 14 | −11 | −2 |
| Free Cash Flow | 0 | −8 | 34 | −5 | 10 | −4 | −23 | −3 |
| CFO/EBITDA | 4 | −82 | 81 | 35 | −96 | 39 | 234 | 1,464 |
Ratios
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 47 | 6 | 4 | 14 | 6 | 11 | 19 |
| Inventory Days | 123 | 93 | 135 | 174 | 167 | 186 | 214 | 187 |
| Days Payable | 89 | 33 | 32 | 13 | 24 | 31 | 35 | 20 |
| Cash Conversion Cycle | 87 | 107 | 109 | 165 | 157 | 161 | 190 | 186 |
| Working Capital Days | 45 | 85 | 61 | 109 | 156 | 176 | 163 | 145 |
| ROCE % | — | 57% | 67% | 33% | −6% | −4% | 1% | 3% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Nureca insights
60 extracted metrics across FY18–FY27.
Documents
- General announcements 21 Oct 2026
Frequently Asked Questions about Nureca
What does Nureca Ltd do?
Where is Nureca Ltd (NURECA) listed?
Which sector does Nureca Ltd belong to?
What is the PE ratio of Nureca Ltd?
What is the 52-week high and low of Nureca Ltd?
Does Nureca Ltd pay dividends?
What is the Return on Equity (ROE) of Nureca Ltd?
Company Information
Incorporated in 2016, Nureca Ltd is in the business of Home Healthcare and Wellness Products.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NURECA.md for Nureca Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.